DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases

Information source: Dana-Farber Cancer Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Metastatic Renal Cell Carcinoma

Intervention: Pazopanib (Drug); Sorafenib (Drug); Radium-223 (Drug)

Phase: Phase 1

Status: Recruiting

Sponsored by: Dana-Farber Cancer Institute

Official(s) and/or principal investigator(s):
Rana McKay, MD, Principal Investigator, Affiliation: Dana-Farber Cancer Institute

Overall contact:
Rana McKay, MD, Phone: (617) 632-4524, Email: rmckay5@partners.org

Summary

This research study is comparing different drug combinations as a possible treatment for metastatic renal cell carcinoma (mRCC) and bone metastases. The names of the study interventions involved in this study are:

- Combination of Radium-223 and Sorafenib

- Combination of Radium-223 and Pazopanib

Clinical Details

Official title: Phase I Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Biomarkers of osteoblast and osteoclast activity

Secondary outcome:

Symptomatic skeletal events (SSEs)

Time to SSE

Quality of life using the FKSI-19

Pain using the Brief Pain Inventory (Short Form)

Analgesic use

Overall response rate by RECIST version 1.1

Duration of response by RECIST version 1.1

Overall survival

Progression-free survival

Response as determined by PERCIST Criteria

Response as determined by MDA Bone Response Criteria

Response within bone biomarker subgroups

Time to first SSE within bone biomarker subgroups

PFS within bone biomarker subgroups

OS within bone biomarker subgroups

Detailed description: The FDA (the U. S. Food and Drug Administration) has not approved the combination of sorafenib and radium-223 or the combination of pazopanib and radium-223 as a treatment for any disease. Sorafenib and pazopanib are both approved as single agents for the treatment of metastatic renal cell carcinoma. Additionally, radium-223 is FDA approved for the treatment of advanced prostate cancer and has shown to have effects on prostate cancer. Currently, there are limited options for patients with metastatic renal cell cancer who also have bone metastases. Bone metastases are related to a higher incidence of skeletal complications, including skeletal pain, fractures, spinal cord compression, and an increase in the amount of calcium in blood. Such skeletal complications could result in radiation or surgery to the bone. Since radium-223 is shown to be effective for patients with metastatic prostate cancer who also have bone metastases, researchers want to explore radium-223 with VEGF-targeting therapies to understand how the drug combinations affect safety, quality of life, incidence of skeletal complications, and the progression of cancer.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age ≥ 18 years.

- Documented pathologic diagnosis of RCC. All subtypes eligible including but not

limited to clear cell, papillary, chromophobe, collecting duct carcinoma, medullary carcinoma, and unclassified categories. Sarcomatoid and rhabdoid differentiation are allowed.

- Presence of at least one metastatic bone lesion(s). Patients with non-measurable

bone-only disease are allowed.

- ECOG performance status of 0-2 (Appendix A).

- Must have adequate organ and bone marrow function.

- Absolute neutrophil count (ANC) ≥ 1500/mm3 (without use of G-CSF 4 weeks prior

to enrollment).

- Platelet count ≥100,000/mm3.

- Hemoglobin ≥ 9 g/dL (transfusions allowed).

- ALT and AST ≤ 3. 0 x the upper limit of normal (ULN).

- Total bilirubin ≤ 1. 5 x ULN. For participants with Gilbert's disease ≤ 3. 0

mg/dL.

- Calculated creatinine clearance ≥ 30 mL/min using the Cockroft-gault equation.

- Urine protein-to-creatinine (UPC) ratio ≤ 2 mg/mg creatinine or 24-hour urine

protein < 2 g.

- Recovery to baseline or ≤ grade 1 CTCAE version 4. 0 from toxicities related to any

prior treatment, unless adverse events are clinically non-significant and/or stable on supportive therapy.

- Capable of understanding and complying with the protocol requirements and has signed

the informed consent document.

- Sexually active participants and their partners must agree to use medically accepted

methods of contraception.

- Female participants of childbearing potential must not be pregnant at screening.

- Sexually active participants (men and women) must agree to use highly effective

contraceptive methods during the course of the study and for 6 months after completing treatment with radium-223. Exclusion Criteria:

- For patients in the sorafenib cohort, no prior therapy with sorafenib is allowed and

at least 1 line of prior therapy is required including prior: VEGF-targeting therapy (such as sunitinib, axitinib, tivozanib, bevacizumab), mTOR-targeting therapy (such as everolimus, temsirolimus), immunotherapy (such as anti-PD-1 or anti-PD-L1), cytokine therapy (such as interleukin-2, IFN-a) or cytotoxic systemic chemotherapy allowed.

- For patients in the pazopanib cohort, no prior systemic therapy for mRCC is allowed,

with the exception of prior cytokine therapy (such as interleukin-2, IFN-a), immunotherapy (such as anti-PD-1 or anti-PD-L1), or supportive therapies (such as zoledronic acid, denosumab).

- Receipt of any type of small molecular kinase inhibitor (including investigational

kinase inhibitors) within 2 weeks of enrollment or receipt of any anti-cancer therapy (including investigational therapy, monoclonal antibodies, cytokine therapy) within 3 weeks of enrollment.

- Radiation therapy for bone metastases within 2 weeks, other external radiation

therapy within 4 weeks of enrollment.

- Received prior hemibody external radiotherapy.

- Prior therapy with radium-223 or systemic radiotherapy (such as samarium, strontium).

- Known brain metastases or cranial epidural disease unless adequately treated with

radiotherapy, radiosurgery, or surgery and stable for at least 4 weeks of enrollment as documented by MRI or CT imaging. Treated brain metastases are defined as having no ongoing requirement for steroids (must be off steroids for at least 4 weeks) and no evidence of progression or hemorrhage after treatment for at least 4 weeks of enrollment as documented by MRI or CT imaging.

- Imminent or established spinal cord compression based on clinical and/or imaging. In

patients with untreated imminent or established spinal cord compression, treatment with standard of care as clinically indicated should be completed at least 4 weeks before enrollment.

- The subject has uncontrolled, significant intercurrent or recent illness including,

but not limited to, the following conditions:

- Cardiovascular disorders:

- Symptomatic congestive heart failure, unstable angina pectoris, serious

cardiac arrhythmias.

- uncontrolled hypertension defined as sustained BP > 150 mm Hg systolic or >

100 mm Hg diastolic despite optimal antihypertensive treatment.

- Stroke (including transient ischemic attack), myocardial infarction, or

other ischemic event within 12 weeks of enrollment.

- Thromboembolic event (such as deep venous thrombosis, pulmonary embolism)

within 4 weeks of enrollment.

- GI disorders including those associated with a high risk of perforation or

fistula formation:

- Tumors invading the GI-tract, active peptic ulcer disease, inflammatory

bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic or biliary duct, or gastric outlet obstruction.

- Abdominal fistula, gastrointestinal perforation, bowel obstruction, or

intraabdominal abscess within 12 weeks before enrollment. Note: Complete healing of an intra-abdominal abscess must be confirmed before enrollment.

- Clinically significant hematuria, hematemesis, or hemoptysis of > 0. 5 teaspoon

(2. 5 ml) of red blood, or other history of significant bleeding (such as pulmonary hemorrhage) within 4 weeks of enrollment.

- Other clinically significant disorders such as:

- Active infection requiring systemic treatment, infection with human

immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or chronic hepatitis B or C infection.

- Serious non-healing wound or ulcer.

- Malabsorption syndrome.

- Symptomatic hypothyroidism.

- Moderate to severe hepatic impairment (Child-Pugh B or C).

- Requirement for hemodialysis or peritoneal dialysis.

- History of solid organ transplantation.

- Major surgery (such as GI surgery) within 6 weeks of enrollment. However,

subjects who have had a nephrectomy may be enrolled 4 weeks after surgery, providing there are no wound-healing complications. Subjects with clinically relevant ongoing complications from prior surgery are not eligible. The following are not considered to be major procedures: Thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures.

- QTcF > 470 msec within 4 weeks of enrollment. If the initial QTcF is found to be

> 470 ms, two additional EKGs separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is ≤ 470 ms, the subject meets eligibility in this regard.

- Pregnant or lactating females.

- Inability to swallow tablets or capsules.

- Previously identified allergy or hypersensitivity to components of the study

treatment formulations.

- Diagnosis of another malignancy within 2 years of enrollment, except for

superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy by the principal investigator

Locations and Contacts

Rana McKay, MD, Phone: (617) 632-4524, Email: rmckay5@partners.org

Dana Farber Cancer Institute, Boston, Massachusetts 02115, United States; Recruiting
Rana McKay, MD, Phone: 617-632-4524, Email: rmckay5@partners.org
Meghara Walsh, RN, Phone: 617-632-5264, Email: mwalsh10@partners.org
Rana McKay, MD, Principal Investigator

Massachusetts General Hospital, Boston, Massachusetts 02114, United States; Not yet recruiting
M. Dror Michaelson, MD, PhD, Phone: 617-643-1770, Email: DMICHAELSON1@PARTNERS.ORG
Carol Gurski, RN, Phone: 617-643-1770, Email: cgurski@partners.org
M.Dror Michaelson, MD, Principal Investigator

Additional Information

Starting date: April 2015
Last updated: June 2, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017